CD274 and neoplasm: Overall, no differences were observed in subgroup analyses of age, sex, ECOG performance−status score, Stage of disease, lymph node station, histologic features, PD-L1 tumor proportion score, region, planned neoadjuvant platinum agent, pCR status and MPR status.